Prophylactic Assays
|
TLR2 |
Lipopeptide |
E7 CTL epitope |
(7272. Shen KY, Song YC, Chen IH, Chong P, Liu SJ. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother. 2014;10(11):3241-50, http://dx.doi.org/10.4161/hv.29275. http://dx.doi.org/10.4161/hv.29275...
) |
TLR4 |
AS04, LPS derivative |
VLP (L1) |
(6868. Van den Bergh JM, Guerti K, Willemen Y, Lion E, Cools N, Goossens H, et al. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med. 2014;18(7):1372-80, http://dx.doi.org/10.1111/jcmm.12284. http://dx.doi.org/10.1111/jcmm.12284...
) |
TLR5 |
Flagellin |
E6/E7 peptide |
(7777. Nguyen CT, Hong SH, Ung TT, Verma V, Kim SY, Rhee JH, et al. Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clin Exp Vaccine Res. 2013;2(2):128-34, http://dx.doi.org/10.7774/cevr.2013.2.2.128. http://dx.doi.org/10.7774/cevr.2013.2.2....
) |
Therapeutic Assays
|
TLR3 |
Poly (I:C) |
E7 peptide |
(7373. Chen S, Ou R, Tang J, Deng X, Wu Y, van Velkinburgh JC, et al. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150. Cancer Epidemiol. 2013;37(2):172-8, http://dx.doi.org/10.1016/j.canep.2012.10.005. http://dx.doi.org/10.1016/j.canep.2012.1...
) |
TLR3/TLR7 |
Resiquimod/Poly (I:C) |
E7 DNA |
(7575. Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A. Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol. 2014;159(8):1951-60, http://dx.doi.org/10.1007/s00705-014-2024-4. http://dx.doi.org/10.1007/s00705-014-202...
) |
TLR7 |
Imiquimod |
E7-calreticulin DNA |
(7676. Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res. 2014;20(21):5456-67, http://dx.doi.org/10.1158/1078-0432.CCR-14-0344. http://dx.doi.org/10.1158/1078-0432.CCR-...
) |
TLR7/TLR9 |
Imiquimod/CpG |
E7 DNA |
(7474. Lescaille G, Pitoiset F, Macedo R, Baillou C, Huret C, Klatzmann D, et al. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum Gene Ther. 2013;24(5):533-44, http://dx.doi.org/10.1089/hum.2012.037. http://dx.doi.org/10.1089/hum.2012.037...
) |
Prophylactic and Therapeutic Assays
|
TLR2/TLR4 |
HMGB1 peptide |
E7 DNA |
(7878. Talebi S, Bolhassani A, Sadat SM, Vahabpour R, Agi E, Shahbazi S. Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPVn vaccines. Biomed Pharmacother. 2017;85:148-54, http://dx.doi.org/10.1016/j.biopha.2016.11.115. http://dx.doi.org/10.1016/j.biopha.2016....
) |